KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895 · see citing works

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · see citing works

Systematic identification of genomic markers of drug sensitivity in cancer cells

Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · see citing works

RAS Proteins and Their Regulators in Human Disease

Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · see citing works

Lentivirus-delivered stable gene silencing by RNAi in primary cells.

Stewart, S. A., Dykxhoorn, D. M., Palliser, D., Mizuno, H., Yu, E. Y., An, D., Sabatini, D., Chen, I. S. Y., Hahn, W., Sharp, P., et al. (2003) · RNA: A publication of the RNA Society · doi:10.1261/rna.2192803 · Cited by 1,619 · see citing works

BRAF mutation predicts sensitivity to MEK inhibition

Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,317 · see citing works

Targeting RAS–ERK signalling in cancer: promises and challenges

Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163 · see citing works

Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer

Jonkers, J., Meuwissen, R. L. J., van der Gulden, H. M. L., Peterse, H. L., van der Valk, M., & Berns, A. J. M. (2001) · Nature Genetics · doi:10.1038/ng747 · Cited by 1,053 · see citing works

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations

Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786 · see citing works

Regulation of RAF protein kinases in ERK signalling

Lavoie, H., & Therrien, M. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3979 · Cited by 683 · see citing works

Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context

Guerra, C. E., Mijimolle, N., Dhawahir, A., Dubus, P. R., Barradas, M., Serrano, M., Campuzano, V., & Barbacid, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00191-0 · Cited by 566 · see citing works

Frequency-Modulated Pulses of ERK Activity Transmit Quantitative Proliferation Signals

Albeck, J. G., Mills, G. B., & Brugge, J. S. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.11.002 · Cited by 490 · see citing works

A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma

Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415 · see citing works

The clinical development of MEK inhibitors

Zhao, Y., & Adjei, A. A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.83 · Cited by 403 · see citing works

A combinatorial strategy for treating KRAS-mutant lung cancer

Manchado, E., Weissmueller, S., Morris, J. P., Chen, C.-C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J. T., Gainor, J. F., Corcoran, R. B., et al. (2016) · Nature · doi:10.1038/nature18600 · Cited by 403 · see citing works

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv072 · Cited by 349 · see citing works

Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival

Drosten, M., Dhawahir, A., Sum, E. Y. M., Urosevic, J., Lechuga, C. G., Esteban, L. M., Castellano, E., Guerra, C., Santos, E., & Barbacid, M. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.7 · Cited by 347 · see citing works

Higher-Order Assemblies in a New Paradigm of Signal Transduction

Wu, H. (2013) · Cell · doi:10.1016/j.cell.2013.03.013 · Cited by 346 · see citing works

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With <i>KRAS</i> -Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

Jänne, P. A., van den Heuvel, M. M., Barlesi, F., Cobo, M., Mazieres, J., Crinò, L., Orlov, S., Blackhall, F., Wolf, J., Garrido, P., et al. (2017) · JAMA · doi:10.1001/jama.2017.3438 · Cited by 335 · see citing works

The mutational landscapes of genetic and chemical models of Kras-driven lung cancer

Westcott, P. M. K., Halliwill, K. D., To, M. D., Rashid, M., Rust, A. G., Keane, T., Delrosario, R., Jen, K., Gurley, K. E., Kemp, C. J., et al. (2014) · Nature · doi:10.1038/nature13898 · Cited by 333 · see citing works

Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors

Lito, P., Saborowski, A., Yue, J., Solomon, M., Joseph, E., Gadal, S., Saborowski, M., Kastenhuber, E., Fellmann, C., Ohara, K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.011 · Cited by 324 · see citing works

Wildtype Kras2 can inhibit lung carcinogenesis in mice

Zhang, Z., Wang, Y., Vikis, H. G., Johnson, L., Liu, G., Li, J., Anderson, M. W., Sills, R. C., Hong, H. L. T., Devereux, T. R., et al. (2001) · Nature Genetics · doi:10.1038/ng721 · Cited by 295 · see citing works

Inhibition of RAS function through targeting an allosteric regulatory site

Spencer-Smith, R., Koide, A., Zhou, Y., Eguchi, R. R., Sha, F., Gajwani, P., Santana, D., Gupta, A., Jacobs, M., Herrero-Garcia, E., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2231 · Cited by 283 · see citing works

Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway

Nan, X., Tamgüney, T. M., Collisson, E. A., Lin, L.-J., Pitt, C., Galeas, J., Lewis, S., Gray, J. W., McCormick, F., & Chu, S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509123112 · Cited by 273 · see citing works

In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C

Hunter, J. C., Gurbani, D., Ficarro, S. B., Carrasco, M. A., Lim, S. M., Choi, H. G., Xie, T., Marto, J. A., Chen, Z., Gray, N. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404639111 · Cited by 242 · see citing works

Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling

Young, A., Lou, D., & McCormick, F. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0231 · Cited by 211 · see citing works

GTP-Dependent K-Ras Dimerization

Muratcioglu, S., Chavan, T. S., Freed, B. C., Jang, H., Khavrutskii, L., Freed, R. N., Dyba, M. A., Stefanisko, K., Tarasov, S. G., Gursoy, A., et al. (2015) · Structure · doi:10.1016/j.str.2015.04.019 · Cited by 202 · see citing works

XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer

Kim, J., McMillan, E., Kim, H. S., Venkateswaran, N., Makkar, G., Rodriguez-Canales, J., Villalobos, P., Neggers, J. E., Mendiratta, S., Wei, S., et al. (2016) · Nature · doi:10.1038/nature19771 · Cited by 202 · see citing works

Inhibition of KRAS -Driven Tumorigenicity by Interruption of an Autocrine Cytokine Circuit

Zhu, Z., Aref, A. R., Cohoon, T. J., Barbie, T. U., Imamura, Y., Yang, S., Moody, S. E., Shen, R. R., Schinzel, A. C., Thai, T. C., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0646 · Cited by 193 · see citing works

Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance

Castellano, E., Sheridan, C., Thin, M. Z., Nye, E. L., Spencer‐Dene, B., Diefenbacher, M. E., Moore, C., Kumar, M. S., Murillo, M. M., Gronroos, E. C., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.012 · Cited by 184 · see citing works

KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer

Burgess, M. R., Hwang, E., Mroue, R., Bielski, C. M., Wandler, A. M., Huang, B. J., Firestone, A. J., Young, A., Lacap, J. A., Crocker, L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.01.020 · Cited by 183 · see citing works

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

Ambrogio, C., Goméz-López, G., Falcone, M., Vidal, A., Nadal, E., Crosetto, N., Blasco, R. B., Fernández-Marcos, P. J., Sánchez‐Céspedes, M., Ren, X., et al. (2016) · Nature Medicine · doi:10.1038/nm.4041 · Cited by 175 · see citing works

Prognostic and Predictive Value in<i>KRAS</i>in Non–Small-Cell Lung Cancer: A Review

Wood, K., Hensing, T., Malik, R., & Salgia, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0405 · Cited by 164 · see citing works

H-Ras forms dimers on membrane surfaces via a protein–protein interface

Lin, W., Iversen, L., Tu, H., Rhodes, C., Christensen, S. M., Iwig, J. S., Hansen, S. D., Huang, W. Y. C., & Groves, J. T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321155111 · Cited by 156 · see citing works

N-Ras Forms Dimers at POPC Membranes

Güldenhaupt, J., Rudack, T., Bachler, P. S., Mann, D., Triola, G., Waldmann, H., Kötting, C., & Gerwert, K. B. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.08.043 · Cited by 148 · see citing works

Kras regulatory elements and exon 4A determine mutation specificity in lung cancer

To, M. D., Wong, C. E., Karnezis, A. N., Rosario, R. D., Lauro, R. D., & Balmain, A. (2008) · Nature Genetics · doi:10.1038/ng.211 · Cited by 117 · see citing works

RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally

Miller, M. S., & Miller, L. D. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2011.00100 · Cited by 76 · see citing works

Covalent Guanosine Mimetic Inhibitors of G12C KRAS

Xiong, Y., Lu, J., Hunter, J., Li, L., Scott, D., Choi, H. G., Lim, S. M., Manandhar, A., Gondi, S., Sim, T., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00373 · Cited by 66 · see citing works

A flow cytometric method to detect protein‐protein interaction in living cells by directly visualizing donor fluorophore quenching during CFP→YFP fluorescence resonance energy transfer (FRET)

He, L., Olson, D. P., Wu, X., Karpova, T., McNally, J. G., & Lipsky, P. E. (2003) · Cytometry Part A · doi:10.1002/cyto.a.10073 · Cited by 62 · see citing works

Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged

Chapman, P. B., Solit, D. B., & Rosen, N. X. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.017 · Cited by 52 · see citing works

The wild‐type Ras: road ahead

Singh, A. K., Sowjanya, A. P., & Ramakrishna, G. (2005) · The FASEB Journal · doi:10.1096/fj.04-2584hyp · Cited by 47 · see citing works

Structural Dynamics in Ras and Related Proteins upon Nucleotide Switching

Harrison, R. A., Lu, J., Carrasco, M. A., Hunter, J., Manandhar, A., Gondi, S. R., Westover, K. D., & Engen, J. R. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.10.017 · Cited by 37 · see citing works

Modeling Lung Cancer Evolution and Preclinical Response by Orthotopic Mouse Allografts

Ambrogio, C., Carmona, F. J., Vidal, A., Falcone, M., Nieto, P., Romero, O. A., Puertas, S., Vizoso, M., Nadal, E., Poggio, T., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1606 · Cited by 32 · see citing works

Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors

Brant, R., Sharpe, A. D., Liptrot, T., Dry, J. R., Harrington, E. A., Barrett, J. C., Whalley, N., Womack, C., Smith, P. D., & Hodgson, D. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0021 · Cited by 28 · see citing works

Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma

Köhler, J., Catalano, M., & Ambrogio, C. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170530093100 · Cited by 15 · see citing works

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304 · see citing works

RAS-targeted therapies: is the undruggable drugged?

Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · see citing works

Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development

Salo‐Ahen, O. M. H., Alanko, I., Bhadane, R. N., Bonvin, A. M. J. J., Honorato, R. V., Hossain, S., Juffer, A. H., Kabedev, A., Lahtela-Kakkonen, M. K., Larsen, A. S., et al. (2020) · Processes · doi:10.3390/pr9010071 · Cited by 693 · see citing works

Therapeutic strategies to target RAS-mutant cancers

Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420 · see citing works

Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma

Hu, K., Li, K., Lv, J., Feng, J., Chen, J., Wu, H., Cheng, F., Jiang, W., Wang, J., Pei, H., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124049 · Cited by 409 · see citing works

A model for RAS mutation patterns in cancers: finding the sweet spot

Li, S., Balmain, A., & Counter, C. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0076-6 · Cited by 384 · see citing works

Targeting the untargetable KRAS in cancer therapy

Liu, P., Wang, Y., & Li, X. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.002 · Cited by 366 · see citing works

KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0368 · Cited by 259 · see citing works

KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation

Tran, T. H., Chan, A. H., Young, L. C., Bindu, L. K., Neale, C., Messing, S. A. J., Dharmaiah, S., Taylor, T. E., Denson, J.-P., Esposito, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21422-x · Cited by 245 · see citing works

A pan-cancer analysis of synonymous mutations

Sharma, Y., Miladi, M., Dukare, S., Boulay, K., Caudron‐Herger, M., Groß, M., Backofen, R., & Diederichs, S. (2019) · Nature Communications · doi:10.1038/s41467-019-10489-2 · Cited by 226 · see citing works

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition

Adderley, H., Blackhall, F. H., & Lindsay, C. R. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.049 · Cited by 196 · see citing works

The path to the clinic: a comprehensive review on direct KRASG12C inhibitors

Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 192 · see citing works

RAS: Striking at the Core of the Oncogenic Circuitry

Gimple, R. C., & Wang, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00965 · Cited by 174 · see citing works

Pharmacological targeting of RAS: recent success with direct inhibitors

O’Bryan, J. P. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.021 · Cited by 153 · see citing works

Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling

Ponsioen, B., Post, J. B., Amorie, J. R. B. D., Laskaris, D., van Ineveld, R. L., Kersten, S., Bertotti, A., Sassi, F. P., Sipieter, F., Cappe, B., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00654-5 · Cited by 140 · see citing works

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer

Dagogo-Jack, I., Martinez, P., Yeap, B. Y., Ambrogio, C., Ferris, L. A., Lydon, C., Nguyen, T., Jessop, N. A., Iafrate, A. J., Johnson, B. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2062 · Cited by 130 · see citing works

Mechanisms of Resistance to KRASG12C Inhibitors

Dunnett-Kane, V., Nicola, P. A., Blackhall, F. H., & Lindsay, C. R. (2021) · Cancers · doi:10.3390/cancers13010151 · Cited by 120 · see citing works

Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling

Terrell, E. M., Durrant, D., Ritt, D. A., Sealover, N. E., Sheffels, E., Spencer-Smith, R., Esposito, D., Zhou, Y., Hancock, J. F., Kortum, R. L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.004 · Cited by 115 · see citing works

Therapeutic targeting of RAS: New hope for drugging the “undruggable”

Khan, I., Rhett, J. M., & O’Bryan, J. P. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118570 · Cited by 109 · see citing works

Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer

Bielski, C. M., Donoghue, M. T. A., Gadiya, M. M., Hanrahan, A. J., Won, H. H., Chang, M. T., Jonsson, P., Penson, A. V., Gorelick, A. N., Harris, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.003 · Cited by 103 · see citing works

Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival

Varghese, A. M., Perry, M., Chou, J. F., Nandakumar, S., Muldoon, D. M., Erakky, A., Zucker, A., Fong, C. J., Mehine, M. M., Nguyen, B., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03362-3 · Cited by 119 · see citing works

The impact of oncogenic RAS on redox balance and implications for cancer development

Lim, J. K. M., & Leprivier, G. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2192-y · Cited by 101 · see citing works

Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC

Yang, F., Wen, Y., Wang, C., Zhou, Y., Zhou, Y., Zhang, Z.-M., Liu, T., & Lu, X. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114088 · Cited by 109 · see citing works

KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe

Bery, N., Legg, S., Debreczeni, J., Breed, J., Embrey, K., Stubbs, C., Kolasinska-Zwierz, P., Barrett, N., Marwood, R., Watson, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10419-2 · Cited by 97 · see citing works

Machine learning–driven multiscale modeling reveals lipid-dependent dynamics of RAS signaling proteins

Ingólfsson, H. I., Neale, C., Carpenter, T. S., Shrestha, R., López, C. A., Tran, T. H., Oppelstrup, T., Bhatia, H., Stanton, L. G., Zhang, X., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113297119 · Cited by 92 · see citing works

RAS variant signalling

Mo, S. P., Coulson, J. M., & Prior, I. A. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180173 · Cited by 85 · see citing works

Assessment of mutation probabilities of KRAS G12 missense mutants and their long-timescale dynamics by atomistic molecular simulations and Markov state modeling

Pantsar, T., Rissanen, S., Dauch, D., Laitinen, T., Vattulainen, I., & Poso, A. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006458 · Cited by 85 · see citing works

KIAA1429 promotes tumorigenesis and gefitinib resistance in lung adenocarcinoma by activating the JNK/ MAPK pathway in an m6A-dependent manner

Lin, X., Ye, R., Li, Z., Zhang, B., Huang, Y., Du, J., Wang, B., Meng, H., Xian, H., Zhang, X., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100908 · Cited by 84 · see citing works

KRAS G12C Mutations in NSCLC: From Target to Resistance

Addeo, A., Banna, G. L., & Friedlaender, A. (2021) · Cancers · doi:10.3390/cancers13112541 · Cited by 84 · see citing works

ADAM17: An Emerging Therapeutic Target for Lung Cancer

Saad, M. I., Rose‐John, S., & Jenkins, B. J. (2019) · Cancers · doi:10.3390/cancers11091218 · Cited by 80 · see citing works

Two Distinct Structures of Membrane‐Associated Homodimers of GTP‐ and GDP‐Bound KRAS4B Revealed by Paramagnetic Relaxation Enhancement

Lee, K., Fang, Z., Enomoto, M., Gasmi-Seabrook, G. M. C., Zheng, L., Koide, S., Ikura, M., & Marshall, C. B. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202001758 · Cited by 79 · see citing works

Extracellular‐signal‐regulated kinase/mitogen‐activated protein kinase signaling as a target for cancer therapy: an updated review

Najafi, M., Ahmadi, A., & Mortezaee, K. (2019) · Cell Biology International · doi:10.1002/cbin.11187 · Cited by 78 · see citing works

Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma

Menotti, M., Ambrogio, C., Cheong, T.-C., Pighi, C., Mota, I. A., Cassel, S. H., Compagno, M., Wang, Q., Dall’Olio, R., Minero, V. G., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0262-9 · Cited by 76 · see citing works

Therapeutics Targeting Mutant KRAS

Thein, K. Z., Biter, A. B., & Hong, D. S. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-080819-033145 · Cited by 75 · see citing works

Multivalent assembly of KRAS with the RAS-binding and cysteine-rich domains of CRAF on the membrane

Fang, Z., Lee, K., Huo, K.-G., Gasmi-Seabrook, G. M. C., Zheng, L., Moghal, N., Tsao, M., Ikura, M., & Marshall, C. B. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914076117 · Cited by 74 · see citing works

Current Approaches in NSCLC Targeting K-RAS and EGFR

Aran, V., & Omerović, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225701 · Cited by 74 · see citing works

Precision therapy in RAS mutant colorectal cancer

Dienstmann, R., Connor, K., Byrne, A. T., Fridman, W. H., Lambrechts, D., Sadanandam, A., Trusolino, L., Prehn, J. H. M., Tabernero, J., & Kolch, W. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.12.051 · Cited by 73 · see citing works

Phosphorylated Rho–GDP directly activates mTORC2 kinase towards AKT through dimerization with Ras–GTP to regulate cell migration

Senoo, H., Kamimura, Y., Kimura, R., Nakajima, A., Sawai, S., Sesaki, H., & Iijima, M. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0348-8 · Cited by 73 · see citing works

A “Tug of War” Maintains a Dynamic Protein–Membrane Complex: Molecular Dynamics Simulations of C-Raf RBD-CRD Bound to K-Ras4B at an Anionic Membrane

Li, Z., Prakash, P., & Buck, M. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00593 · Cited by 71 · see citing works

A structural model of a Ras–Raf signalosome

Mysore, V. P., Zhou, Z.-W., Ambrogio, C., Li, L., Kapp, J. N., Lu, C., Wang, Q., Tucker, M. R., Okoro, J. J., Nagy‐Davidescu, G., et al. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00667-6 · Cited by 69 · see citing works

Crystal Structure Reveals the Full Ras–Raf Interface and Advances Mechanistic Understanding of Raf Activation

Cookis, T., & Mattos, C. (2021) · Biomolecules · doi:10.3390/biom11070996 · Cited by 62 · see citing works

DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters

Sutton, M. N., Lü, Z., Li, Y.-C., Zhou, Y., Huang, T., Reger, A. S., Hurwitz, A. M., Palzkill, T. G., Logsdon, C. D., Liang, X., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.045 · Cited by 68 · see citing works

Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer

Li, S., Liu, S., Deng, J., Akbay, E. A., Hai, J., Ambrogio, C., Zhang, L., Zhou, F., Jenkins, R. W., Adeegbe, D. O., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3438 · Cited by 67 · see citing works

RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade

Nokin, M., Mira, A., Patrucco, E., Ricciuti, B., Cousin, S., Soubeyran, I., José, S. S., Peirone, S., Caizzi, L., Michelina, S. V., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51828-2 · Cited by 68 · see citing works

K-Ras prenylation as a potential anticancer target

Baranyi, M., Buday, L., & Hegedűs, B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09902-w · Cited by 62 · see citing works

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant–driven tumor growth

Shin, S., Kim, J., Park, S.-W., Jun, S.-Y., Kweon, H.-J., Choi, D.-K., Lee, D., Cho, Y. B., & Kim, Y. (2020) · Science Advances · doi:10.1126/sciadv.aay2174 · Cited by 63 · see citing works

K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function

Cao, S., Chung, S., Kim, S., Li, Z., Manor, D., & Buck, M. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004021 · Cited by 62 · see citing works

The membrane surface as a platform that organizes cellular and biochemical processes

Leonard, T. A., Loose, M., & Martens, S. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.06.001 · Cited by 61 · see citing works

ERK1/2: An Integrator of Signals That Alters Cardiac Homeostasis and Growth

Gilbert, C. J., Longenecker, J. Z., & Accornero, F. (2021) · Biology · doi:10.3390/biology10040346 · Cited by 60 · see citing works

ProtCID: a data resource for structural information on protein interactions

Xu, Q., & Dunbrack, R. L. (2020) · Nature Communications · doi:10.1038/s41467-020-14301-4 · Cited by 60 · see citing works

Uncovering a membrane-distal conformation of KRAS available to recruit RAF to the plasma membrane

Van, Q. N., López, C. A., Tonelli, M., Taylor, T. E., Niu, B., Stanley, C. B., Bhowmik, D., Tran, T. H., Frank, P. H., Messing, S. A. J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006504117 · Cited by 58 · see citing works

KRASQ61H Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non–Small Cell Lung Cancer

Zhou, Z.-W., Ambrogio, C., Bera, A. K., Li, Q., Li, X.-X., Li, L., Son, J., Gondi, S., Li, J., Campbell, E., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0448 · Cited by 60 · see citing works

The Ins and Outs of RAS Effector Complexes

Kiel, C., Matallanas, D., & Kölch, W. (2021) · Biomolecules · doi:10.3390/biom11020236 · Cited by 57 · see citing works

The RAS-ERK pathway: A route for couples

Santos, E., & Crespo, P. (2018) · Science Signaling · doi:10.1126/scisignal.aav0917 · Cited by 57 · see citing works

Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer

Wiesweg, M., Kasper, S., Worm, K., Herold, T., Reis, H., Sara, L., Metzenmacher, M., Abendroth, A., Darwiche, K., Aigner, C., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0634-0 · Cited by 55 · see citing works

Raf promotes dimerization of the Ras G-domain with increased allosteric connections

Packer, M. R., Parker, J. A., Chung, J. K., Li, Z., Lee, Y. K., Cookis, T., Guterres, H., Alvarez, S. A., Hossain, M. A., Donnelly, D. P., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2015648118 · Cited by 55 · see citing works

Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions

Watterson, A., & Coelho, M. A. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01063-x · Cited by 58 · see citing works

Consensus on the RAS dimerization hypothesis: Strong evidence for lipid-mediated clustering but not for G-domain-mediated interactions

Simanshu, D. K., Philips, M. R., & Hancock, J. F. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.03.008 · Cited by 55 · see citing works

High-throughput, single-particle tracking reveals nested membrane domains that dictate KRasG12D diffusion and trafficking

Lee, Y., Phelps, C. E., Huang, T., Mostofian, B., Wu, L., Zhang, Y., Tao, K. X., Chang, Y. H., Stork, P. A., Gray, J. W., et al. (2019) · eLife · doi:10.7554/elife.46393 · Cited by 56 · see citing works

Targeting the α4–α5 dimerization interface of K-RAS inhibits tumor formation in vivo

Khan, I., Spencer-Smith, R., & O’Bryan, J. P. (2019) · Oncogene · doi:10.1038/s41388-018-0636-y · Cited by 54 · see citing works

40 Years of RAS—A Historic Overview

Fernández‐Medarde, A., Rivas, J. D. L., & Santos, E. (2021) · Genes · doi:10.3390/genes12050681 · Cited by 53 · see citing works

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

Sale, M. J., Balmanno, K., Saxena, J., Ozono, E., Wojdyła, K., McIntyre, R. E., Gilley, R., Woroniuk, A., Howarth, K., Hughes, G. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09438-w · Cited by 52 · see citing works

DIRAS3: An Imprinted Tumor Suppressor Gene that Regulates RAS and PI3K-driven Cancer Growth, Motility, Autophagy, and Tumor Dormancy

Bildik, G., Liang, X., Sutton, M. N., Bast, R. C., & Lü, Z. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0331 · Cited by 50 · see citing works

Mechanisms of Ras Membrane Organization and Signaling: Ras Rocks Again

Abankwa, D., & Gorfe, A. A. (2020) · Biomolecules · doi:10.3390/biom10111522 · Cited by 48 · see citing works

Targeting KRAS mutant lung cancer: light at the end of the tunnel

Drosten, M., & Barbacid, M. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13168 · Cited by 47 · see citing works

Oligomeric organization of membrane proteins from native membranes at nanoscale spatial and single-molecule resolution

Walker, G., Brown, C., Ge, X., Kumar, S., Muzumdar, M. D., Gupta, K., & Bhattacharyya, M. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01547-4 · Cited by 46 · see citing works

Therapeutic gene regulation using pyrrole–imidazole polyamides

Yu, Z., Pandian, G. N., Hidaka, T., & Sugiyama, H. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.02.001 · Cited by 46 · see citing works

Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies

Rozengurt, E., & Eibl, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02499-y · Cited by 47 · see citing works

KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges

Passiglia, F., Malapelle, U., Re, M. D., Righi, L., Pagni, F., Furlan, D., Danesi, R., Troncone, G., & Novello, S. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.06.023 · Cited by 43 · see citing works

The role of wild-type RAS in oncogenic RAS transformation

Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42 · see citing works

Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of <i>KRAS</i> Mutations in Non–Small Cell Lung Cancer

Ricciuti, B., Son, J., Okoro, J. J., Mira, A., Patrucco, E., Eum, Y., Wang, X., Paranal, R., Wang, H., Lin, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2719 · Cited by 42 · see citing works

Not all RAS mutations are equal: A detailed review of the functional diversity of RAS hot spot mutations

Burge, R. A., & Hobbs, G. A. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2021.07.004 · Cited by 44 · see citing works

Conformational resolution of nucleotide cycling and effector interactions for multiple small GTPases determined in parallel

Killoran, R. C., & Smith, M. J. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008653 · Cited by 41 · see citing works

Oncogenic KRAS G12D mutation promotes dimerization through a second, phosphatidylserine–dependent interface: a model for KRAS oligomerization

Lee, K.-Y., Enomoto, M., Gebregiworgis, T., Gasmi-Seabrook, G. M. C., Ikura, M., & Marshall, C. B. (2021) · Chemical Science · doi:10.1039/d1sc03484g · Cited by 41 · see citing works

BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS

Röck, R., Mayrhofer, J. E., Torres‐Quesada, O., Enzler, F., Raffeiner, A., Raffeiner, P., Feichtner, A., Huber, R. G., Koide, S., Taylor, S. S., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav8463 · Cited by 36 · see citing works

Current smartphone-assisted point-of-care cancer detection: Towards supporting personalized cancer monitoring

Le, L. T. P., Nguyen, A. H. Q., Tu, L. M. T. P. P. L. M., Ngo, H. T. T., Wang, X., Cunningham, B. T., Valera, E., Bashir, R., Taylor-Robinson, A. W., & Do, C. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117681 · Cited by 39 · see citing works

KRAS: A Promising Therapeutic Target for Cancer Treatment

Wu, H.-Z., Xiao, J., Xiao, S., & Cheng, Y. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190905164144 · Cited by 41 · see citing works

Allostery in membrane proteins

Cournia, Z., & Chatzigoulas, A. (2020) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2020.03.006 · Cited by 39 · see citing works

Approaches to inhibiting oncogenic K-Ras

Gorfe, A. A., & Cho, K. (2019) · Small GTPases · doi:10.1080/21541248.2019.1655883 · Cited by 36 · see citing works

Oncogenic context shapes the fitness landscape of tumor suppression

Blair, L. M., Juan, J. M., Sebastian, L., Tran, V. B., Nie, W., Wall, G. D., Gerceker, M., Lai, I. K., Apilado, E. A., Grenot, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42156-y · Cited by 37 · see citing works

TAK1 Phosphorylates RASSF9 and Inhibits Esophageal Squamous Tumor Cell Proliferation by Targeting the RAS/MEK/ERK Axis

Shi, H. M., Ju, Q., Mao, Y., Wang, Y., Ding, J., Liu, X., Tang, X., & Sun, C. (2021) · Advanced Science · doi:10.1002/advs.202001575 · Cited by 35 · see citing works

Targeting KRAS in PDAC: A New Way to Cure It?

He, Q., Liu, Z., & Wang, J. (2022) · Cancers · doi:10.3390/cancers14204982 · Cited by 36 · see citing works

Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth

Tang, R., Shuldiner, E. G., Kelly, M. R., Murray, C. W., Hebert, J. D., Andrejka, L., Tsai, M. K., Hughes, N. W., Parker, M. I., Cai, H., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01049-w · Cited by 37 · see citing works

Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy

Huang, Y., Cheng, W., Kuo, T.-T., Yang, J., Wu, Y., Wu, H., Lo, C.-C., Hsieh, C.-Y., Wong, S., Lu, C., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00720-x · Cited by 34 · see citing works

RAS Nanoclusters: Dynamic Signaling Platforms Amenable to Therapeutic Intervention

Van, Q. N., Prakash, P., Shrestha, R., Balius, T. E., Turbyville, T. J., & Stephen, A. G. (2021) · Biomolecules · doi:10.3390/biom11030377 · Cited by 34 · see citing works

KARATE: PKA-induced KRAS4B-RHOA-mTORC2 supercomplex phosphorylates AKT in insulin signaling and glucose homeostasis

Senoo, H., Murata, D., Wai, M., Arai, K., Iwata, W., Sesaki, H., & Iijima, M. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.09.001 · Cited by 33 · see citing works

Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in RAS-mutant cancer cells

Sheffels, E., Sealover, N. E., Theard, P. L., & Kortum, R. L. (2019) · Small GTPases · doi:10.1080/21541248.2019.1611168 · Cited by 30 · see citing works

Natural product manoalide promotes EGFR-TKI sensitivity of lung cancer cells by KRAS-ERK pathway and mitochondrial Ca2+ overload-induced ferroptosis

Ni, Y., Liu, J., Zeng, L., Yang, Y., Liu, L., Yao, M., Chai, L., Zhang, L., Li, Y., Zhang, L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1109822 · Cited by 32 · see citing works

Investigation of GTP-dependent dimerization of G12X K-Ras variants using ultraviolet photodissociation mass spectrometry

Mehaffey, M. R., Schardon, C. L., Novelli, E. T., Cammarata, M. B., Webb, L. J., Fast, W. L., & Brodbelt, J. S. (2019) · Chemical Science · doi:10.1039/c9sc01032g · Cited by 31 · see citing works

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer

Wang, H., Lv, Q., Xu, Y., Cai, Z., Zheng, J., Cheng, X., Dai, Y., Janne, P. A., Ambrogio, C., & Köhler, J. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.012 · Cited by 31 · see citing works

RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics

Kattan, W. E., & Hancock, J. F. (2020) · Biochemical Journal · doi:10.1042/bcj20190839 · Cited by 31 · see citing works

Signaling pathways downstream to receptor tyrosine kinases: targets for cancer treatment

Cordover, E., & Minden, A. (2020) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2020.101 · Cited by 30 · see citing works

Crosstalk between KRAS, SRC and YAP Signaling in Pancreatic Cancer: Interactions Leading to Aggressive Disease and Drug Resistance

Rozengurt, E., & Eibl, G. (2021) · Cancers · doi:10.3390/cancers13205126 · Cited by 30 · see citing works

Biology, pathology, and therapeutic targeting of RAS

Rhett, J. M., Khan, I., & O’Bryan, J. P. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.05.002 · Cited by 28 · see citing works

Limited survival and impaired hepatic fasting metabolism in mice with constitutive Rag GTPase signaling

Arregui, C. D. L. C., Plata-Gómez, A. B., Deleyto-Seldas, N., Garcı́a, F., Ortega-Molina, A., Abril-Garrido, J., Rodriguez, E., Nemazanyy, I., Tribouillard, L., Martino, A. D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23857-8 · Cited by 28 · see citing works

Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1

Han, Y., Yu, C.-C., Fine, S. A., Youssof, A. L., Yang, Y., Yan, J., Karg, D. C., Cheung, E. C., Friedman, R. A., Ying, H., et al. (2021) · Oncogene · doi:10.1038/s41388-021-02040-9 · Cited by 27 · see citing works

Down-regulated m6A reader FTO destabilizes PHF1 that triggers enhanced stemness capacity and tumor progression in lung adenocarcinoma

Ning, J., Wang, F., Bu, J., Zhu, K., & Liu, W. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01125-y · Cited by 28 · see citing works

Small GTPase peripheral binding to membranes: molecular determinants and supramolecular organization

Peurois, F., Peyroche, G., & Cherfils, J. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170525 · Cited by 27 · see citing works

The Ras dimer structure

Rudack, T., Teuber, C., Scherlo, M., Güldenhaupt, J., Schartner, J., Lübben, M., Klare, J. P., Gerwert, K. B., & Kötting, C. (2021) · Chemical Science · doi:10.1039/d1sc00957e · Cited by 27 · see citing works

Exploring CRD mobility during RAS/RAF engagement at the membrane

Nguyen, K., López, C. A., Neale, C., Van, Q. N., Carpenter, T. S., Natale, F. D., Travers, T. S., Tran, T. H., Chan, A. H., Bhatia, H., et al. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.06.035 · Cited by 27 · see citing works

P3.02-066 Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma

Ambrogio, C., Köhler, J., Zhou, Z., Wang, H., Paranal, R. M., Capelletti, M., Caffarra, C., Li, S., Lv, Q., Gondi, S. R., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.1595 · Cited by 1 · see citing works

Wild-type KRAS mediates growth inhibition and resistance to MEK inhibitors through dimerization with mutant KRAS in lung adenocarcinoma

Ambrogio, C., Köhler, J., Zhou, Z., Wang, H., Paranal, R. M., Capelletti, M., Caffarra, C., Li, S., Lv, Q., Santamarı́a, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx361 · Cited by 3 · see citing works

IA02 Insights into KRAS Biology to Identify Potential Therapeutic Strategies

Ambrogio, C. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.003 · Cited by 1 · see citing works

Abstract IA05: Dimerization is critical for the functions of wild-type and mutant KRAS

Ambrogio, C. (2020) · Molecular Cancer Research · doi:10.1158/1557-3125.ras18-ia05

Dimerization Is Critical for the Functions of Wild-type and Mutant KRAS

(2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2018-013 · Cited by 1 · see citing works